论文部分内容阅读
目的:通过对69例脑转移癌放射治疗的疗效及预后因素分析,了解影响患者预后的因素,以便改进治疗方法。方法:71例接受了放射治疗的脑转移癌患者,可评估病例69例,采用全脑放疗或联合局部缩野放射治疗,根据性别、年龄、KPS评分、原发灶状态、转移灶的数目、RPA分级、放疗剂量以及是否转移等进行统计分析,对不同生存情况进行比较。结果:全组中位生存时间7.1个月。放疗总剂量>30Gy组中位生存期(8.2个月)明显高于放疗总剂量≤30Gy组(2.3个月),χ2=4.403,P=0.036。与预后相关的因素有KPS评分、RPA分级、原发灶状态以及是否转移等。患者预后与性别、年龄和转移灶的数目未见明显相关。结论:全脑放疗联合局部缩野放射治疗可有效缓解脑转移癌患者症状,并延长生存期和提高生活质量。
OBJECTIVE: To analyze the efficacy and prognostic factors of radiotherapy for 69 patients with brain metastases, and to understand the factors influencing the prognosis of patients so as to improve the treatment. Methods: Totally 71 patients with brain metastases who underwent radiotherapy were evaluated in 69 cases. Whole brain radiotherapy or combined local radiotherapy was used. According to gender, age, KPS score, the status of primary tumor, the number of metastases, RPA grading, radiotherapy dose and whether to transfer such as statistical analysis of different survival conditions were compared. Results: The median survival time of the whole group was 7.1 months. The median survival time (8.2 months) of total radiation dose> 30Gy was significantly higher than that of the total radiation dose ≤30Gy (2.3 months), χ2 = 4.403, P = 0.036. Prognostic factors associated with KPS score, RPA classification, the status of the primary tumor and whether the transfer. The prognosis of patients was not significantly correlated with gender, age and the number of metastases. Conclusion: Whole brain radiotherapy combined with local shrinking radiation therapy can effectively alleviate the symptoms of patients with brain metastases and prolong the survival period and improve the quality of life.